Jenny Foss Abrahamsen

Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age.

Jenny Foss Abrahamsen, A Andersen, Einar Hannisdal et al. · Journal of Clinical Oncology · 1993 · 159 citations

Medicine, Geriatric Medicine, Oncology +17

Long-term risk of second malignancy after treatment of Hodgkin’s disease: the influence of treatment, age andfollow-up time

A. F. Abrahamsen, A Andersen, Ole Nome et al. · Annals of Oncology · 2002 · 111 citations

Medicine, Oncology, Cancer Epidemiology +12

Cryopreserving human peripheral blood progenitor cells with 5‐percent rather than 10‐percent DMSO results in less apoptosis and necrosis in CD34+ cells

Jenny Foss Abrahamsen, Anne M. Bakken, Øystein Bruserud · Transfusion · 2002 · 100 citations

Life Sciences, Cell Biology, Hematology +17

Circadian Variations in Clock Gene Expression of Human Bone Marrow CD34+ Cells

Oleg Tsinkalovsky, Rune Smaaland, Benedikte Rosenlund et al. · Journal of Biological Rhythms · 2007 · 56 citations

Life Sciences, Hematology, Molecular Biology +17

The viability of cryopreserved PBPC depends on the DMSO concentration and the concentration of nucleated cells in the graft

Knut Liseth, Jenny Foss Abrahamsen, Solfrid Bjørsvik et al. · Cytotherapy · 2005 · 54 citations

Life Sciences, Cell Biology, Stem Cell Transplantation +6